/
Adverse Event Collection Recommendations
Adverse Event Collection Recommendations
Project Scope |
This project team will create a White Paper with recommendations for Adverse Event Collection Instructions, with a focus on Phase 2-4 clinical trials. This project will build upon a paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices. |
Project Leads | Emails |
---|---|
Aimee Basile, Otsuka Pharmaceutical | |
Mary Nilsson, Eli Lilly | |
Nicola Newton, PHUSE Project Assistant |
CURRENT STATUS Q2 2024 |
---|
|
Objectives & Deliverables | Timelines |
Publish White Paper | Q2 2024 |
Published Deliverables | Date |
---|---|
White Paper - The Adverse Event Collection Recommendations | 11-Jun-2024 |
Blog – Investigator Assessment of Causality – Opportunity for Simplification? | 15-Dec-2021 |
Adverse Event Collection & Treatment Emergent Collection: Version 1.0 | 27-Aug-2020 |
, multiple selections available,
Related content
Recommendations for Adverse Event Collection and Treatment Emergent Definition
Recommendations for Adverse Event Collection and Treatment Emergent Definition
More like this
Listings for Clinical Study Report
Listings for Clinical Study Report
More like this
Estimands in Oncology Safety Task Force
Estimands in Oncology Safety Task Force
More like this
Safety Analytics Webinar Series: Interdisciplinary Safety Evaluation for Learning and Decision-Making
Safety Analytics Webinar Series: Interdisciplinary Safety Evaluation for Learning and Decision-Making
More like this